Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy

被引：0
|
作者：
Delasos, Lukas
Berube, Bryan
Nikoo, Maedeh Zokaei
Wei, Wei
Shapiro, Marc A.
Hassan, Khaled Aref
Stevenson, James
Adjei, Alex A.
Pennell, Nathan A.
机构：
[1] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH USA
[2] Cleveland Clin, Cleveland, OH USA
[3] Cleveland Clin Fdn, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8611
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment
    Zheng, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S646 - S647
  • [32] Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure
    Ding, H.
    Xu, T.
    Wang, X.
    Cheng, W.
    Fang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S670 - S671
  • [33] Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib
    Papazyan, Thomas
    Denis, Marc G.
    Sagan, Christine
    Raimbourg, Judith
    Herbreteau, Guillaume
    Pons-Tostivint, Elvire
    TARGETED ONCOLOGY, 2024, 19 (04) : 611 - 621
  • [34] Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC
    Zhao, Binghao
    Yao, Longping
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (05)
  • [35] Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor
    Mao, Y.
    Huang, Z.
    Cai, D.
    Lou, R.
    Shen, C.
    Wang, X.
    Liu, Y.
    Qi, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S638 - S638
  • [36] Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
    Zheng, Mei-Mei
    Li, Yang-Si
    Sun, Hao
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : E12 - E14
  • [37] Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting
    Uprety, Dipesh
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 371 - 374
  • [38] Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
    Yan, Dan
    BIOMEDICINES, 2023, 11 (11)
  • [39] How I treat patients with EGFR-mutant NSCLC
    Aggarwal, Charu
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (11): : 387 - 387
  • [40] Neoadjuvant Osimertinib in EGFR-Mutant Stage IIIA/B NSCLC - A Phase 2 Open-Label Pilot Study
    Kian, W.
    Roisman, L. C.
    Chernomordikov, E.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Keren, S.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1100 - S1100
12345